Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
Clinical trial NCT07708714 · RECRUITING
Trial details
- NCT number
- NCT07708714
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-13
- Primary completion
- 2030-11-30
- Enrollment
- 250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.